Prevents coronavirus disease 2019 (COVID-19). Sold as Xocova. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Ensitrelvir (sold as Xocova), first approved May 29, 2026, with 0 new uses approved and 0 published complete response letters.
| Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVIDLong COVID, Post Acute Sequelae of COVID-19 · Timothy Henrich | Phase 2 | Active, not recruiting | Dec 8, 2023 |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)COVID-19 · University of Oxford | Phase 2 | Recruiting | Sep 13, 2021 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Shionogi